PER-028-04已完成未知
MULTICENTER STUDY RANDOMIZED, DOUBLE-BLIND, CONTROLLED WITH PLACEBO, OF PARALLEL GROUPS, WITH MULTIPLE DOSE (7DAYS) AND DOSE RANGE TO EVALUATE THE EFFICACY AND SAFETY OF 4 DOSES OF QAB149 (50, 100, 200 AND 400 UG) ADMINISTERED THROUGH INHALER OF DRY POWDER MULTIDOSIS AND 1 DOSAGE OF QAB149 (400UG) ADMINISTERED THROUGH DRY POWDER INHALER MONODOSIS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2004年7月8日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Diagnosis of COPD
- •Age 40-75 years
- •Smoking history
排除标准
- •Other serious disease
- •Allergy to QAB149
- •Respiratory tract infection
研究者
相似试验
已完成
不适用
Study In People With Type 2 DiabetesPER-061-05GLAXOSMITHKLINE PERU S.A.,
已完成
不适用
TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES WITH AN INVESTIGATIONAL NEW DRUGPER-084-02GLAXOSMITHKLINE RESEARCH TRIANGLE PARK,
已完成
不适用
8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe HypertensioPER-068-06OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA®)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE. - N/AOsteoarthritis of the kneeClassification code 10031161EUCTR2004-001713-34-GBPfizer Limited516
已完成
不适用
MULTICENTRIC, RANDOMIZED, DOUBLE-BLIND STUDY, IN PARALLEL GROUPS, WITH ACTIVE CONTROL, OF 24 WEEKS OF DURATION, TO EVALUATE THE EFFICACY OF THE COMBINATION VALSARTAN / HYDROCHLOROTHYAZIDE VERSUS AMLODIPINE ON THE SYSTOLIC ARTERIAL PRESSURE IN PATIENTS WITH MODERATE HYPERTENSION WITH RISK FACTORS AND / OR CARDIOVASCULAR CONCOMYANT DISEASE-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-010-03OVARTIS BIOSCIENSES PERU S.A.,